Collegium Pharmaceutical Inc. has announced a new share repurchase program valued at $150 million, set to run through December 31, 2026. This initiative replaces the previous $150 million program, which expired on June 30, 2025. The company has returned $222 million to shareholders through repurchase programs since 2021.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.